Last updated: August 18, 2026
Dimethyl fumarate is a mature oral small-molecule product with substantial generic competition, but its excipient system still creates commercial opportunities in delayed-release delivery, capsule manufacturing, stability control, taste and gastrointestinal tolerability, and differentiated fumarate products. The core opportunity is not a new active ingredient. It is a robust, scalable, regulatorily defensible formulation platform that controls dissolution, limits gastric exposure, and supports reliable bioequivalence.
What products contain dimethyl fumarate?
Dimethyl fumarate is marketed primarily as an oral delayed-release treatment for relapsing forms of multiple sclerosis. The reference product is Tecfidera, developed and commercialized by Biogen.
| Product |
Active ingredient |
Dosage form |
Company |
FDA status |
Commercial relevance |
| Tecfidera |
Dimethyl fumarate |
Delayed-release capsule |
Biogen |
Approved March 27, 2013 |
Reference product |
| Generic dimethyl fumarate |
Dimethyl fumarate |
Delayed-release capsule |
Multiple ANDA sponsors |
Approved beginning in 2020 |
Price competition |
| Vumerity |
Diroximel fumarate |
Delayed-release capsule |
Biogen |
Approved October 30, 2019 |
Fumarate franchise replacement and tolerability strategy |
| Bafiertam |
Monomethyl fumarate |
Delayed-release capsule |
Banner Life Sciences |
Approved September 28, 2020 |
Competing fumarate product |
Tecfidera is supplied in 120 mg and 240 mg delayed-release capsules. The product uses an enteric or delayed-release coating to reduce release in the stomach and deliver dimethyl fumarate beyond the gastric environment.
Dimethyl fumarate is a small molecule. It is not eligible for biosimilar designation under the U.S. biologics framework. Competitive risk therefore comes from abbreviated new drug applications, 505(b)(2) products, reformulations, and alternative fumarate compounds rather than biosimilars.
What excipients are used in Tecfidera?
The Tecfidera label identifies excipients in the capsule content and delayed-release coating. The principal excipient categories include:
| Excipient category |
Representative materials reported for Tecfidera |
Functional role |
| Bulking and compression aid |
Microcrystalline cellulose |
Supports pellet or tablet mass and mechanical integrity |
| Disintegrant |
Croscarmellose sodium |
Promotes dispersion after release |
| Glidant and processing aid |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate |
Reduces manufacturing friction |
| Coating polymer |
Methacrylic acid copolymer |
Provides pH-dependent delayed release |
| Plasticizer |
Triethyl citrate |
Reduces coating brittleness |
| Coating aid |
Talc |
Controls tack, friction and coating processability |
| Capsule shell |
Gelatin and colorants |
Provides oral dosage form and product identification |
Source: Biogen, Tecfidera U.S. Prescribing Information.
The commercial value of this system comes from its functional combination. No single excipient creates the product’s performance. The release profile depends on polymer chemistry, coating weight gain, plasticizer ratio, particle-size distribution, capsule fill uniformity, and manufacturing conditions.
Why does the enteric coating matter?
Dimethyl fumarate can cause gastrointestinal adverse events, including flushing, diarrhea, nausea, abdominal pain and vomiting. A delayed-release system can reduce immediate gastric exposure and improve the product’s clinical usability.
A typical methacrylic acid copolymer coating remains comparatively resistant in low-pH gastric fluid and dissolves at a higher intestinal pH. Triethyl citrate increases film flexibility. Talc improves anti-tacking performance and can affect coating permeability and mechanical durability.
For a generic sponsor, matching the reference product requires more than identifying the listed ingredients. The sponsor must control:
- dissolution in acidic media;
- transition from acidic to intestinal pH;
- capsule rupture and dose dispersion;
- coating thickness and weight gain;
- active-ingredient content uniformity;
- impurity formation during storage;
- moisture uptake;
- mechanical stress during packaging and transport.
What excipient strategy is most commercially attractive for dimethyl fumarate?
The strongest excipient strategy is a platform approach based on delayed-release performance, not a simple substitution of one inactive ingredient for another.
Use a pH-dependent polymer system
Methacrylic acid copolymers remain the most direct route to an enteric profile. Commercial alternatives include different grades of methacrylic acid and ethyl acrylate copolymers, methacrylic acid and methyl methacrylate copolymers, and aqueous or organic polymer dispersions.
A sponsor can pursue differentiated performance through:
- a lower coating weight with higher polymer efficiency;
- improved resistance to gastric fluid;
- faster intestinal release;
- lower coating-process temperature;
- reduced residual solvent exposure;
- better resistance to capsule abrasion;
- reduced variability across manufacturing sites.
The regulatory burden increases when the polymer grade, coating architecture or release mechanism differs materially from the reference product. A formulation change that affects release may require a more extensive bioequivalence and chemistry, manufacturing and controls package.
Optimize plasticizer and anti-tacking systems
Triethyl citrate is widely used in enteric coatings, but formulation teams can evaluate alternative plasticizers such as polyethylene glycol, propylene glycol or acetyl tributyl citrate where compatible with the polymer system.
The commercial objective is not simply to reduce ingredient cost. The formulation must preserve:
- film flexibility;
- storage stability;
- dissolution after aging;
- resistance to cracking;
- low tack during fluid-bed coating;
- acceptable capsule appearance.
Talc, glyceryl monostearate and other anti-tacking agents can influence coating efficiency and equipment throughput. A lower-talc or talc-free coating may appeal to customers seeking simplified excipient declarations, but it must maintain process robustness and dissolution control.
Control moisture and fumarate degradation
Dimethyl fumarate is sensitive to formulation and storage conditions that can affect impurity growth and release performance. Moisture control should be integrated across the formulation and packaging system.
Commercially relevant controls include:
- low-moisture excipients;
- controlled-humidity granulation or coating;
- high-barrier blister packaging;
- desiccant-containing bottles;
- moisture-resistant capsule shells;
- validated hold times for coated intermediates;
- impurity monitoring for fumarate-related degradants.
Packaging is part of the excipient strategy in practical terms. A lower-cost formulation that requires high-barrier packaging may lose its cost advantage.
Evaluate capsule-shell alternatives
Hard gelatin capsules are established and inexpensive. Hypromellose capsules can offer advantages where sponsors seek vegetarian positioning, lower moisture interaction or improved supply-chain flexibility.
A capsule-shell change can affect:
- disintegration;
- water activity;
- oxygen and moisture transmission;
- fill-weight variability;
- printing and visual differentiation;
- stability;
- dissolution after storage.
Hypromellose is therefore a possible product-differentiation tool, but the commercial benefit depends on whether payers, prescribers and patients value the change. For a generic product, a capsule-shell switch may create unnecessary regulatory complexity unless it solves a measurable stability or manufacturing problem.
What formulation patents protect dimethyl fumarate products?
Dimethyl fumarate’s original composition-of-matter protection is expired in the United States. Remaining patent value has historically concentrated on formulation, dosage form and method-of-use claims.
| Protection category |
Typical claim subject |
Commercial effect |
| Active ingredient |
Dimethyl fumarate or fumaric acid ester composition |
Expired or weak for current U.S. generic competition |
| Delayed-release formulation |
Enteric-coated capsule, pellet or multiparticulate system |
Can delay or complicate generic entry |
| Dosage regimen |
Specific dosing schedules or treatment methods |
Potential method-of-use enforcement |
| Manufacturing |
Coating, particle formation or product processing |
Usually narrower and harder to enforce broadly |
| Alternative fumarate |
Diroximel fumarate or monomethyl fumarate |
Supports product switching rather than direct DMF protection |
U.S. Patent No. 6,509,376, associated with fumaric acid ester compositions and uses, was central to Tecfidera’s original patent position. Later Tecfidera-related patents addressed formulation and other product attributes. Exact live coverage depends on the current FDA Orange Book record, patent-term adjustments, pediatric extensions, terminal disclaimers and litigation outcomes.
FDA Orange Book listings should be reviewed by NDA and patent number before relying on any expiration date. The Orange Book identifies patents submitted by the NDA holder, but it does not establish that every claim remains enforceable against every product design.
When did dimethyl fumarate lose U.S. exclusivity?
Tecfidera received five years of new chemical entity exclusivity beginning with FDA approval in 2013, followed by additional regulatory exclusivity associated with its approval and pediatric development. Generic entry began after patent and litigation barriers were resolved or narrowed.
The key commercial dates are:
| Event |
Date or period |
| Tecfidera FDA approval |
March 27, 2013 |
| Five-year NCE exclusivity period |
Ended in 2018 |
| First major U.S. generic approvals |
2020 |
| Broad generic market formation |
2020 onward |
| Vumerity approval |
October 30, 2019 |
| Bafiertam approval |
September 28, 2020 |
Biogen faced generic challenges to Tecfidera patents, including Paragraph IV certifications. Litigation with generic manufacturers produced settlements and court decisions that affected launch timing. The first generic approvals did not eliminate the possibility of later formulation, process or method-of-use disputes.
Which companies challenged Tecfidera patents?
Generic challengers included Mylan, Zydus and other ANDA sponsors. Mylan’s challenge became a major part of the U.S. Tecfidera patent dispute. In 2020, the U.S. District Court for the Northern District of West Virginia held Biogen’s Tecfidera patent invalid for lack of written description, clearing the way for generic competition. The Federal Circuit later addressed related appellate issues.
The dispute illustrates the weakness of relying on a broad formulation patent when the underlying claimed invention does not adequately support the full scope of the claims. For future excipient-driven products, a patent estate should contain data across:
- polymer grades;
- coating weight ranges;
- pH-release profiles;
- dissolution windows;
- impurity thresholds;
- capsule and multiparticulate architectures;
- manufacturing parameters;
- clinical or pharmacokinetic performance.
A single broad claim to a delayed-release fumarate formulation is less durable than a layered estate supported by comparative data.
What is the Orange Book status of dimethyl fumarate?
Tecfidera is listed in the FDA Orange Book as an approved drug product with associated patents. Generic dimethyl fumarate delayed-release capsules are approved through the ANDA pathway and are therapeutically equivalent where assigned an “AB” rating against the reference product.
The Orange Book has four practical functions for dimethyl fumarate:
- It identifies listed patents submitted for Tecfidera.
- It records expiration dates and pediatric extensions.
- It supports Paragraph IV certification analysis.
- It identifies therapeutic-equivalence ratings for approved generics.
A sponsor assessing market entry should distinguish between:
- listed patents that have expired;
- patents removed or delisted after litigation;
- patents subject to settlement restrictions;
- patents that may cover only a method of use;
- non-Orange Book patents that may still support trade-secret or process litigation.
Method-of-use patents may not block a generic’s approval if the labeling can omit the patented indication or dosing instruction. Formulation patents are more directly relevant to the product a generic company intends to sell.
What generic entry risks exist for a new dimethyl fumarate formulation?
A new product faces five principal risks.
Bioequivalence failure
The reference product has a delayed-release profile. A formulation that matches total exposure but releases at the wrong pH or time may fail comparative testing or raise FDA review questions.
Excipient-driven variability
Changes in polymer grade, particle size, plasticizer level or capsule-shell composition can alter dissolution after accelerated and long-term stability testing.
Patent infringement
A new formulation may avoid an expired active-ingredient patent but still implicate claims directed to delayed release, coating composition, dosing or manufacturing.
Product-switching by Biogen
Vumerity gives Biogen a product-level response to generic Tecfidera pressure. A sponsor entering with generic dimethyl fumarate competes against both low-price generics and branded fumarate switching strategies.
Price erosion
Dimethyl fumarate is an oral solid with several potential manufacturers. Generic pricing can decline rapidly after multiple approvals, reducing the commercial value of premium excipients unless they generate measurable manufacturing savings or product differentiation.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can pursue the dimethyl fumarate market through five channels.
Enteric polymer systems
Suppliers can package a complete polymer, plasticizer and anti-tacking system supported by dissolution data. The strongest proposition is a ready-to-use aqueous dispersion that reduces development time and coating variability.
Low-moisture excipients
Microcrystalline cellulose, disintegrants, glidants and capsule shells with controlled moisture profiles can address stability and impurity concerns.
Coating process technology
Fluid-bed coating equipment, in-line weight-gain monitoring and process analytical technology can reduce batch failure risk and improve site-to-site transfer.
High-barrier packaging
Blister films, desiccant systems and moisture-resistant bottles can support longer shelf life and lower impurity growth.
Formulation development services
Contract development organizations can offer reference-product characterization, dissolution mapping, design-of-experiments studies, scale-up and comparative stability programs.
How does dimethyl fumarate compare with Vumerity and Bafiertam?
| Attribute |
Tecfidera/generic DMF |
Vumerity |
Bafiertam |
| Active ingredient |
Dimethyl fumarate |
Diroximel fumarate |
Monomethyl fumarate |
| Route |
Oral |
Oral |
Oral |
| Dosage form |
Delayed-release capsule |
Delayed-release capsule |
Delayed-release capsule |
| Main commercial issue |
Generic price competition |
Branded differentiation and switching |
Niche branded competition |
| Excipient opportunity |
Cost-efficient bioequivalent release system |
Tolerability-oriented delivery |
Alternative fumarate formulation |
| Biosimilar exposure |
None |
None |
None |
| Core IP risk |
Formulation and method-of-use patents |
Composition, formulation and use patents |
Composition, formulation and use patents |
Vumerity is commercially important because it gives Biogen an alternative fumarate product while Tecfidera faces generic erosion. Its active ingredient is not dimethyl fumarate, so the product cannot be treated as a direct generic competitor. Bafiertam also competes within the fumarate class but relies on a different active ingredient.
How strong is the dimethyl fumarate patent estate?
The estate is commercially weaker than it was before generic entry because the active ingredient is mature, Tecfidera has multiple generic equivalents, and key litigation reduced the blocking value of certain formulation patents.
The remaining strength is concentrated in:
- specific delayed-release architectures;
- narrower coating and dissolution claims;
- method-of-use patents;
- manufacturing know-how;
- product-switching barriers;
- regulatory complexity around alternative formulations.
A strong new patent program should claim a defined technical relationship between excipients and performance. Examples include a polymer-to-plasticizer ratio that produces a narrow dissolution window, a coating system that reduces impurity formation, or a capsule configuration that maintains release after high-humidity storage.
Claims based only on standard excipients at conventional concentrations are more vulnerable to obviousness attacks. The patent case improves when the formulation produces unexpected pharmacokinetic, stability, tolerability or manufacturing results.
What geographic opportunities exist for dimethyl fumarate excipients?
The United States is the most competitive market and has the clearest ANDA pathway. Europe, Canada, Japan, China, India and Latin America offer additional volume, but regulatory requirements and reference-product availability differ.
| Region |
Main regulatory route |
Excipient opportunity |
| United States |
ANDA or 505(b)(2) |
Bioequivalent delayed-release products and cost reduction |
| European Union |
Generic or hybrid application |
Enteric formulation and centralized supply |
| Canada |
Abbreviated new drug submission |
Capsule and packaging differentiation |
| Japan |
Generic application |
Stability, quality and local manufacturing |
| China |
Generic consistency evaluation |
Localized supply and lower-cost excipient systems |
| India |
Generic approval and export supply |
High-volume formulation manufacturing |
| Latin America |
Country-specific generic pathways |
Flexible packaging and regional sourcing |
For multinational supply, excipient suppliers should prioritize compendial status, impurity control, regional registration support, dual sourcing and consistent polymer performance across plants.
Key Takeaways
- Dimethyl fumarate is a mature oral small molecule with no biosimilar risk.
- Tecfidera’s core commercial formulation uses a delayed-release capsule and pH-dependent enteric coating.
- The highest-value excipient opportunities involve coating polymers, plasticizers, anti-tacking agents, low-moisture excipients, capsule shells and high-barrier packaging.
- Generic entry began in the United States in 2020, creating substantial price pressure.
- Formulation patents remain relevant, but their strength depends on technical data and claim scope.
- Vumerity and Bafiertam create branded competition within the fumarate class.
- The most defensible new IP should link excipient composition to measurable dissolution, stability, pharmacokinetic or manufacturing advantages.
- Commercial success depends on reducing cost and batch variability while preserving bioequivalence.
FAQs
Can a new excipient create a patentable dimethyl fumarate product?
Yes. Patentability is strongest when the excipient produces an unexpected technical result, such as improved stability, reduced gastric release, lower impurity formation or a more consistent intestinal dissolution profile.
Is dimethyl fumarate suitable for a 505(b)(2) product?
A 505(b)(2) pathway may be relevant for a materially different dosage form, release profile, strength, route or clinical use. A conventional bioequivalent delayed-release capsule generally fits the ANDA pathway more directly.
Which excipient is most important in dimethyl fumarate capsules?
The enteric polymer system is usually the most performance-critical component because it controls gastric resistance and intestinal release. Plasticizer and anti-tacking levels can materially affect the polymer film.
Can hypromellose replace gelatin in a dimethyl fumarate capsule?
Hypromellose can be evaluated as an alternative capsule shell, but the change requires assessment of dissolution, moisture transmission, stability, fill performance and regulatory comparability.
Does a generic dimethyl fumarate product need to copy Tecfidera’s excipients?
No. A generic product generally must demonstrate pharmaceutical equivalence and bioequivalence, subject to FDA requirements. It can use different inactive ingredients if the formulation remains acceptable, stable, manufacturable and bioequivalent.
References
-
Biogen. (2024). Tecfidera (dimethyl fumarate) delayed-release capsules: U.S. prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
-
U.S. Food and Drug Administration. (2013). FDA approves new treatment for multiple sclerosis. https://www.fda.gov
-
U.S. Food and Drug Administration. (2019). Vumerity approval package and prescribing information. https://www.fda.gov
-
U.S. Food and Drug Administration. (2020). Bafiertam approval package and prescribing information. https://www.fda.gov
-
United States Patent No. 6,509,376. (2003). Fumaric acid esters for the treatment of multiple sclerosis. U.S. Patent and Trademark Office.
-
United States District Court for the Northern District of West Virginia. (2020). Biogen International GmbH v. Mylan Pharmaceuticals Inc., patent litigation decision concerning Tecfidera.
-
United States Pharmacopeia. (2024). National Formulary: Pharmaceutical excipients and general chapters. United States Pharmacopeial Convention.
